A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-22-0414
Abstract: Abstract Most antibody–drug conjugates (ADC) approved for the treatment of cancer contain protease-cleavable linkers. ADCs that traffic to lysosomes traverse highly acidic late endosomes, while ADCs that recycle to the plasma membrane traffic through mildly… read more here.
Keywords: metxmet antibody; late endosomes; bispecific metxmet; recycling endosomes ... See more keywords